Reverse Remodeling and Functional Improvement of Left Ventricle in Patients with Chronic Heart Failure Treated with Sacubitril/Valsartan: Comparison between Non-Ischemic and Ischemic Etiology

Abstract

Sacubitril/valsartan (SV) has been demonstrated to reduce cardiovascular mortality, hospitalization for heart failure and to induce reverse ventricular remodeling. The present study was designed to confirm the effects of SV in a selected population of patients with HFrEF and to evaluate the different responses between patients with an ischemic or a non-ischemic etiology. A total of 79 patients with indication of SV were recruited prospectively during a timelapse of 4 years. SV was overall associated to a reduction of end-diastolic and end-systolic volume, of NT-proBNP levels, furosemide dosage and NYHA functional class, together with an increase in EF. These changes were more evident in patients with non-ischemic dilated cardiomyopathy, who showed a significant improvement in ventricular volumes, ejection fraction, TAPSE and blood levels of NT-proBNP. Kaplan–Meier curves confirmed a greater benefit in terms of ejection-fraction improvement in non-ischemic patients compared to the ischemic group. The results of the present study confirm the positive effect of SV on NYHA functional class, NT- proBNP, left ventricular volumes and EF in HFrEF patients, showing evidence of association of SV with ventricular remodeling in patients with dilated cardiomyopathy of non-ischemic etiology compared to the ischemic group.

Вибір Блокатора Ренін-Ангіотензин-Альдостеронової Системи Для Лікування Серцевої Недостатності При Гострому Міокардиті

“…M yocarditis is an inflammatory disease of the myocardium, the manifestations of which range from subclinical disease to cardiogenic shock, arrhythmias, and sudden death [6]. The dominant clinical manifestation of severe acute myocarditis (AM) is progressive heart failure (HF), which is associated with the heart muscle inflammatory lesion and, as a result, with the heart contractile function deterioration, left ventricle (LV) dilation, life-threatening arrhythmias and persistent hemodynamic disorders [3,5,9,19].…”